Multivalent anti-SARS-CoV-2 nanobodies
| DWPI Title: Construct for treating coronavirus such as severe acute respiratory syndrome coronavirus 2 delta variant, comprises first binding domain selected from first polypeptide, second polypeptide and third polypeptide comprising first, second and third complementarity determining regions |
| Abstract: Provided herein are asymmetric biparatopic neutralizing nanobody-based antibodies which engage SARS-2 spike in at least two independent epitopes. Several biparatopic constructs showed synergy in neutralizing viral infection of cells. Data also showed that single biparatopic constructs are more effective than the combination of the parental monotopic constructs were at neutralization. The nanobodies that were identified in an initial screen of a large and highly diverse library bind to a single epitope that overlaps with the ACE2 binding site. |
| Use: Construct used for treating coronavirus such as severe acute respiratory syndrome coronavirus 2 delta variant (claimed).No biological data given. |
| Advantage: The construct provides enhanced efficacy, and exhibits binding to coronavirus. |
| Novelty: Construct comprises first binding domain selected from first polypeptide comprising first, second and third complementarity determining regions corresponding to 3 sequences of 7-12 amino acids (SEQ ID NOs: 2, 6, 10), given in the specification, respectively; second polypeptide comprising first, second, and third complementarity determining regions corresponding to 3 sequences of 8-12 amino acids (SEQ ID NOs: 3, 7, 11), given in the specification, respectively; or third polypeptide comprising first, second, and third complementarity determining regions corresponding to 3 sequences of 7-12 amino acids (SEQ ID NOs: 4, 8, 12), given in the specification; first binding comprises portion of antibody including heavy chain portion and having binding domain that binds to coronavirus. |
| Filed: 6/30/2022 |
| Application Number: US17854735A |
| Tech ID: SD 16004.0 |
| This invention was made with Government support under Contract No. DE-NA0003525 awarded by the United States Department of Energy/National Nuclear Security Administration. The Government has certain rights in the invention. |
| Data from Derwent World Patents Index, provided by Clarivate All rights reserved. Republication or redistribution of Clarivate content, including by framing or similar means, is prohibited without the prior written consent of Clarivate. Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license. |